LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Description
This is the first study to evaluate the safety and impact of the combination of pirtobrutinib and LV20.19 CAR-T cells.
Pirtobrutinib is a first-in-class non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. The safe dose of this agent has been identified the BRUIN study as 200 mg daily administered as an oral agent. As a single agent, the toxicity profile has been favorable and does not overlap with other covalent BTK inhibitors with minimal cardiotoxicity and bleeding complications.
Our expert team has 10+ years running successful recruitment campaigns for clinical research sites